RESEARCH ARTICLE

Post-Inhaled Corticosteroid Pulmonary Tuberculosis Increases Lung Cancer in Patients with Asthma

Zhi-Hong Jian1*, Jing-Yang Huang1*, Frank Cheau-Feng Lin2,3, Oswald Ndi Nfor1, Kai-Ming Jhang1,4, Wen-Yuan Ku1, Chien-Chang Ho5, Chia-Chi Lung1,6, Hui-Hsien Pan2,7, Min-Chen Wu8, Ming-Fang Wu2,9*, Yung-Po Liaw1,6*

1 Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung City, Taiwan, 2 School of Medicine, Chung Shan Medical University, Taichung City, Taiwan, 3 Department of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung City, Taiwan, 4 Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan, 5 Department of Physical Education, Fu Jen Catholic University, New Taipei City, Taiwan, 6 Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung City, Taiwan, 7 Department of Pediatrics, Chung Shan Medical University Hospital, Taichung City, Taiwan, 8 Office of Physical Education, Chung Yuan Christian University, Taoyuan City, Taiwan, 9 Divisions of Medical Oncology and Pulmonary Medicine, Chung Shan Medical University Hospital, Taichung City, Taiwan

☯ These authors contributed equally to this work.
* Liawyp@csmu.edu.tw (YPL); mfwu0111@gmail.com (MFW)

Abstract

Purpose
To evaluate the association between post-inhaled corticosteroid (ICS) pulmonary tuberculosis (TB), pneumonia and lung cancer in patients with asthma.

Methods
The study samples were collected from the National Health Insurance Database. Asthmatic patients who were first-time users of ICS between 2003 and 2005 were identified as cases. For each case, 4 control individuals were randomly matched for sex, age and date of ICS use. Cases and matched controls were followed up until the end of 2010. Cox proportional hazard regression was used to determine the hazard ratio for pulmonary infections and lung cancer risk in the ICS users and non-users.

Results
A total of 10,904 first-time users of ICS were matched with 43,616 controls. The hazard ratios for lung cancer were: 2.52 (95% confidence interval [CI], 1.22–5.22; p = 0.012) for individuals with post-ICS TB, 1.28 (95%CI, 0.73–2.26; p = 0.389) for post-ICS pneumonia, 2.31 (95%CI, 0.84–6.38; p = 0.105) for post-ICS pneumonia+TB, 1.08 (95%CI, 0.57–2.03; p = 0.815) for TB, 0.99 (95%CI, 0.63–1.55; p = 0.970) for pneumonia, and 0.32 (95%CI, 0.05–2.32; p = 0.261) for pneumonia+ TB, respectively.
Conclusions

Post-ICS TB increased lung cancer risk in patients with asthma. Because of the high mortality associated with lung cancer, screening tests are recommended for patients with post-ICS TB.

Introduction

Lung cancer is the leading cause of cancer mortality [1]. Although smoking is the major risk factor [2], other factors may also be linked to the increased risk of lung cancer. Recent studies have suggested a strong association between inflammation, infection and lung cancer [3, 4]. Asthma, pulmonary tuberculosis (TB) and pneumonia cause airway inflammation and are also associated with lung cancer [5–7]. The prevalence of asthma (11.9%) in Taiwan is high [8]. Inhaled (ICS) and oral corticosteroids (OCS) are the preferred treatments for airway and systemic inflammation in patients with asthma [9–11].

Minimizing inflammation in the lungs may decrease lung cancer risk. A nested case-control study reported a decreased risk of lung cancer in first-time users of ICS [12]. Moreover, ICS has been associated with a reduced risk of lung cancer in patients with chronic obstructive pulmonary disease (COPD) [13] and COPD who quit smoking [14].

ICS use may suppress the immune system, thereby increasing the risk of TB [15] and pneumonia [16]. TB [17] and pneumonia [7] are risk factors of lung cancer. Co-existing asthma and TB has increased the incidence and mortality of lung cancer [5, 18, 19]. The relationship between pneumonia and TB and lung cancer in asthmatics with ICS use remains unclear. In this study, we evaluated the association between post-ICS pulmonary infections and lung cancer using samples collected from the National Health Insurance Research Database (NHIRD).

Methods

Ethics Statement

This retrospective cohort study was conducted using the NHIRD, Taiwan Cancer Registry Database (TCRD), and National Death Registry Database (NDRD). Individual informed consent was waived because the source data was encrypted and the data extracted was anonymous. This study was approved by the Institutional Review Board of the Chung-Shan Medical University Hospital, Taiwan.

Data Source

The NHIRD included a comprehensive health care information, such as medical diagnoses, prescriptions and information on out and in-patient care. TCRD included demographic characteristics and clinical data, such as age, gender, tumor stage, and primary tumor location. These databases were used to determine the age at diagnosis, person-year follow-up, vital status and potentially unconfirmed cancer diagnoses.

Asthmatic patients and ICS use

We first identified 1,124,939 patients with asthma from 2001–2005 who were free of lung cancer before 2002 using the NHIRD inpatient and ambulatory care orders. Excluded were patients who received ICS before 2002 (n = 16,601) and those with incomplete information regarding sex and registered data (n = 48,209). We enrolled 19,335 asthmatic patients who
received ICS for more than 3 months. Additionally, patients <20 years or >100 years of age were also excluded (n = 1,894).

The ICS included all forms of orally inhaled beclomethasone, budesonide, fluticasone, and ciclesonide whether dispensed alone or in a combination inhaler with an inhaled β2 agonist. Information about the prescription (the dates the drug is prescribed, the number of days of treatment, dosage and the number of refills) were additionally collected. The date of the first use of ICS was referred to as the index date.

Post-ICS pulmonary TB and pneumonia
A diagnosis of pulmonary TB (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code: 010–012, 018, and 137) was confirmed by either 2 outpatient visits or one hospitalization after the index date. Pneumonia (ICD-9-CM codes: 480–486, and 487.0) was confirmed by one hospitalization. Excluded were individuals who were diagnosed with TB or pneumonia before or within 3 months after the index date (n = 4,690).

Identification of lung cancer
Lung cancer was identified using the ICD-9-CM code 162. The histologic types of lung cancer were further confirmed using the TCRD. Patients who died and those that had lung cancer within 2 years after the index date were excluded (n = 1,538).

Study cohorts
Asthmatic patients who were first-time users of ICS between 2003 and 2005 were identified as cases. For each case, 4 controls were randomly matched by sex, age and index date from asthmatic patients who did not use ICS. Cases without matched controls were excluded (n = 309). The final analysis included 10,904 cases and 43,616 matched controls (Fig 1). The eligible participants were followed up until the diagnosis of lung cancer, death, loss to follow-up, or the study end in 2010.

Medications
An OCS user was defined as an individual who took a cumulative dose of 1,680 mg (or 60 mg daily for 4 weeks) of hydrocortisone equivalents or more during the 1-year period after the index date [15]. The OCS prescriptions were converted to hydrocortisone using the following equivalent dose: 4 mg of hydrocortisone = 1 mg of prednisolone = 5 mg of cortisone = 0.8 mg methylprednisolone = 0.8 mg of triamcinolone = 0.4 mg of paramethasone = 0.15mg of betamethasone = 0.15mg of dexamethasone) [20].

The inhaled respiratory medications included short-acting inhaled β2 agonists (SABAs; salbutamol, fenoterol, procaterol, or terbutaline) and long-acting inhaled β2 agonists (LABAs; salmeterol, formoterol, indacaterol, or olodaterol). Other respiratory medications included leukotriene receptor antagonist (LTRA; montelukast) and theophylline.

Variables of exposure
The pre-existing comorbidities were confirmed by either 2 outpatient visits or one hospitalization in one year. They included asthma (ICD-9-CM: 493), COPD (ICD-9-CM: 490, 491, 492, 494, and 496), chronic kidney disease (ICD-9-CM: 585 and 586), diabetes mellitus (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272), liver cirrhosis (ICD-9-CM: 571.2, 571.5, and 571.6), smoking-related cancers (ICD-9-CM: 140–150, 157, 160–161, and 189), autoimmune disease (ICD-9-CM: 710 and 714), atopic dermatitis (ICD-9-CM: 691), and rhinosinusitis.
Fig 1. Flow diagram of the enrollment process. ICS, inhaled corticosteroid; TB, tuberculosis.

doi:10.1371/journal.pone.0159683.g001
Statistical analysis

The SAS 9.3 software (SAS Institute, Cary, NC) was used for data analysis. Descriptive statistical analyses were conducted using the t-test while chi-square test was used to compare the baseline sociodemographic characteristics and comorbidities between ICS users and their controls. At the univariate level, Kaplan-Meier survival plots and log-rank test were used to evaluate the impact of the predictor variables on lung cancer while Cox proportional hazards regression analysis was used at the multivariate levels. A p-value < 0.05 (2-tailed) were considered statistically significant.

Results

Demographic characteristics, medications, comorbidities, and follow-up durations are shown in Table 1. Patients who used ICS had higher rates of lung cancer, TB, pneumonia, respiratory medication use, COPD, hyperlipidemia, rhinosinusitis, and outpatient and inpatient visits for lung disease than their control counterparts.

Kaplan-Meier plots for pneumonia, TB and pneumonia+TB stratified by ICS use are presented in Fig 2. The risks for lung cancer were greatest in patients with post-ICS pulmonary infections. The 5-year cumulative incidences for lung cancer were as follows: post-ICS TB, 6.4%, post-ICS pneumonia+TB, 5.5%, post-ICS pneumonia, 3.5%, TB, 2.2%, pneumonia, 2.1%, and control, 1.2%.

Table 2 shows the adjusted HRs of lung cancer for TB, pneumonia, and pneumonia+TB in asthmatic patients who were users and non-users of ICS compared with controls who were free of pulmonary infections. Post-ICS TB significantly increased the risk of lung cancer (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.22–5.22). The use of ICS (HR, 0.89; 95%CI, 0.69–1.14) was not associated with lung cancer in patients without lung infection. There was no significant association between lung cancer and pulmonary diseases such as TB (HR, 1.08; 95%CI, 0.57–2.03), pneumonia (HR, 0.99; 95%CI, 0.63–1.55) and pneumonia+TB (HR, 0.32; 95%CI, 0.05–2.32) among the control individuals.

Discussion

ICSs are the mainstay treatment to control airway inflammation and acute exacerbations in patients with asthma [21]. They also suppress the immune, thereby increasing the risk of TB and pneumonia [15, 16]. TB and pneumonia cause lung inflammation and have also been associated with lung cancer [3, 5, 7]. However, the impact of post-ICS TB and pneumonia on lung cancer has not been addressed. In this study, a higher risk of lung cancer was observed in patients with post-ICS TB.

In a case-control study to investigate lung cancer risk in non-smoking women (412 cases and 1,253 controls) in the United States, the increased risks associated with previous lung disease were observed in patients with asthma (odds ratio [OR], 1.67; 95%CI, 1.1–2.5) [22]. A case-control study of female lifetime nonsmokers showed an increased risk of lung cancer in asthmatic patients (OR, 4.78; 95%CI, 1.23–18.63) [23]. An increased risk of lung cancer was reported in a Swedish cohort of 92,986 patients with a hospital-discharge diagnosis of asthma [24]. The standardized incidence ratio was 1.51 (95% CI, 1.38–1.65) in men and 1.78 (95% CI,
### Table 1. Characteristics of the Study Population.

|                                | ICS (N = 10,904) | No ICS (N = 43,616) | P-value |
|--------------------------------|------------------|---------------------|---------|
| **Pulmonary disease combinations (%)** |                  |                     |         |
| None                           | 10,022 (91.9)    | 41,227 (94.5)       | <0.001  |
| TB                             | 152 (1.4)        | 496 (1.1)           |         |
| Pneumonia                      | 642 (5.9)        | 1,700 (3.9)         |         |
| Pneumonia+ TB                  | 88 (0.8)         | 193 (0.5)           |         |
| **No. of lung cancer**         | 148              | 469                 | 0.013   |
| **Histologic type of lung cancer (%)** |                  |                     | 0.542   |
| Squamous cell carcinoma        | 32 (21.6)        | 117 (25.0)          |         |
| Adenocarcinoma                 | 63 (42.6)        | 185 (39.5)          |         |
| Small cell carcinoma           | 18 (12.2)        | 43 (9.1)            |         |
| Others                         | 35 (23.6)        | 124 (26.4)          |         |
| **Follow-up time (person-months)** | 5.5×10^5         | 22.1×10^5           |         |
| **Incidence rate of lung cancer (per 10^5 person-months) (95% C.I.)** | 27.1 (23.1–31.9) | 21.2 (19.4–23.2)   | 0.009   |
| **Death from 2004–2008 (%)**   | 942 (8.6)        | 3,291 (7.6)         | <0.001  |
| **Medications (%)**            |                  |                     |         |
| OCS                            | 3,775 (34.6)     | 3,653 (8.4)         | <0.001  |
| LABA                           | 5,308 (48.7)     | 3,455 (7.9)         | <0.001  |
| SABA                           | 9,090 (83.4)     | 13,173 (30.2)       | <0.001  |
| LTRA                           | 2,431 (22.3)     | 1,667 (3.8)         | <0.001  |
| Theophylline                   | 9,999 (91.7)     | 29,369 (67.3)       | <0.001  |
| Statins                        | 1,566 (14.4)     | 5,993 (13.7)        | 0.093   |
| Aspirin                        | 2,626 (24.1)     | 12,076 (27.7)       | <0.001  |
| **Sex (%)**                    |                  |                     | 1.000   |
| Men                            | 6,329 (58.1)     | 25,316 (58.1)       |         |
| Women                          | 4,575 (41.9)     | 18,300 (41.9)       |         |
| **Age (years, %)**             |                  |                     | 1.000   |
| 20–39                          | 1,096 (10.1)     | 4,384 (10.1)        |         |
| 40–59                          | 3,367 (30.9)     | 13,468 (30.9)       |         |
| 60–79                          | 5,399 (49.5)     | 21,596 (49.5)       |         |
| ≥80                            | 1,042 (9.5)      | 4,168 (9.5)         |         |
| **Comorbidities (%)**          |                  |                     |         |
| COPD                           | 5,665 (51.9)     | 5,239 (31.0)        | <0.001  |
| Diabetes                       | 1,830 (16.8)     | 7,606 (17.44)       | 0.106   |
| Hyperlipidemia                 | 1,759 (16.1)     | 7,738 (17.74)       | <0.001  |
| Chronic kidney disease         | 256 (2.4)        | 1,033 (2.37)        | 0.899   |
| Smoking-related cancers        | 95 (0.9)         | 325 (0.75)          | 0.178   |
| Liver cirrhosis                | 128 (1.2)        | 559 (1.28)          | 0.367   |
| Autoimmune disease             | 315 (2.9)        | 1,169 (2.68)        | 0.231   |
| Atopy dermatitis               | 208 (1.9)        | 917 (2.10)          | 0.200   |
| Rhinosinusitis                 | 5,882 (53.9)     | 11,323 (26.0)       | <0.001  |
| **No. of outpatient visits for lung disease 2 years after the index date (%)** |                  |                     |         |
| <15                            | 22.4±14.0        | 7.1±11.3            | <0.001  |
| >15                            | 3,695 (33.9)     | 37,600 (86.2)       | <0.001  |
| **No. of inpatient visits for lung disease 2 years after the index date (%)** |                  |                     |         |
| 0                              | 7,930 (72.7)     | 38,140 (87.4)       | <0.001  |
| ≥1                             | 2,974 (27.3)     | 5,476 (12.6)        |         |

(Continued)
Increased risks of lung cancer have also been reported in Taiwanese men and women [6]. The HRs were 1.36 (95%CI, 1.30–1.41) and 1.26 (95%CI, 1.18–1.34), respectively. In a meta-analysis, asthma has been associated with an increase in the overall relative risk (RR) of lung cancer (RR, 1.28; 95%CI, 1.16–1.41) [25].

Lee et al. analyzed first-time adult users of ICS (9,177 cases and 37,048 controls) and noted that ICS use had a significant linear association with a decreased lung cancer incidence (OR, 0.79; 95%CI, 0.69–0.90) [12]. In a previous study, analyses were conducted on patients newly diagnosed with adult-onset asthma (i.e., 2,117 regular ICS users and 17,732 non-ICS users) [26]. The findings showed no protective effect of regular ICS use on lung cancer. In our study, there was no increased risk of lung cancer in ICS users who were free of pulmonary infections.

There are multiple anti-inflammatory and immunosuppressive effects of glucocorticoids. They suppress macrophage differentiation, production of cytokines, and tumoricidal and microbicidal activities of activated macrophages and inhibit T-cell activation [27]. The joint statement of the American Thoracic Society and the Centers for Disease Control and Prevention acknowledges that taking the equivalent of ≥15 mg/day of prednisone administered for 1 month or more is a risk factor for TB [28]. In a retrospective cohort study of 616 patients with COPD, Kim and colleagues showed that ICS use was an independent risk factor for the development of pulmonary TB in patients who had a normal chest radiograph (HR, 9.08; 95% CI, 1.01–81.43) and those who had radiologic sequelae of prior pulmonary TB (HR, 24.95; 95% CI, 3.09–201.37) [29]. In a nested case-control study based on the Korean national claims database with 4,139 TB cases and 20,583 controls, ICS use had a significant linear association with increased risk of TB (OR, 1.20; 95% CI, 1.08–1.34) [15]. Chung et al. analyzed samples from the NHIRD and found a multiplicative-increase in the risk of TB in ICS and OCS users compared with their non-user counterparts (OR, 4.31; 95% CI, 3.39–5.49) [30]. However, few studies have addressed the association between ICS use and pneumonia in patients with asthma. In a nested case-control study, asthmatic patients who received ICSs were at increased risks for pneumonia and lower respiratory tract infections [31]. The greatest risk was in patients who received higher doses of ICS. Conversely, in a meta-analysis of clinical randomized trials of asthmatics using ICSs (budesonide and fluticasone propionate), patients did not have an increased risk of pneumonia even at higher doses or among the different ICSs [32]. In our study, there were higher rates of TB, pneumonia and pneumonia+TB in ICS users than their non-user counterparts.

In a study involving 4,480 patients with newly diagnosed TB, Yu et al. showed that there was an increased risk of lung cancer in TB patients [33]. The adjusted HR was 3.32 (95% CI, 2.70–4.09). Pneumonia has also been associated with an increased risk of lung cancer (HR, 4.24; 95%CI, 3.96–4.55) [7]. A meta-analysis showed that previous history of pneumonia and

### Table 1. (Continued)

| Urbanization (%) | ICS (N = 10,904) | No ICS (N = 43,616) | P-value |
|------------------|------------------|---------------------|---------|
| High             | 6,325 (58.0)     | 23,575 (54.1)       | <0.001  |
| Mid              | 3,452 (31.6)     | 14,285 (32.7)       |         |
| Low              | 1,127 (10.4)     | 5,756 (13.2)        |         |

CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting inhaled beta-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting beta-agonist; TB, pulmonary tuberculosis.

*Index date was defined as the date of initiation of ICS.

doi:10.1371/journal.pone.0159683.t001

1.55–2.03) in women compared with that of the national population. Increased risks of lung cancer have also been reported in Taiwanese men and women [6]. The HRs were 1.36 (95%CI, 1.30–1.41) and 1.26 (95%CI, 1.18–1.34), respectively. In a meta-analysis, asthma has been associated with an increase in the overall relative risk (RR) of lung cancer (RR, 1.28; 95%CI, 1.16–1.41) [25].
TB conferred RR of 1.43 (95% CI, 1.22–1.68) and 1.76 (95% CI, 1.49–2.08) for lung cancer, respectively [34]. When restricted to nonsmokers, it remained significant for pneumonia (RR, 1.36; 95% CI, 1.10–1.69) and TB (RR, 1.90; 95% CI: 1.45–2.50).
Table 2. Hazard Ratio and 95% Confidence Intervals of Lung Cancer According to ICS and Pulmonary Disease Combinations in Patients with Asthma.

| Pulmonary disease combinations | All patients with asthma |
|--------------------------------|--------------------------|
|                                | HR (95% CI) | P-value |
| None                           | Reference        |
| Only ICS                       | 0.89 (0.69–1.14) | 0.341 |
| Only TB                        | 1.08 (0.57–2.03) | 0.815 |
| Only Pneumonia                 | 0.99 (0.63–1.55) | 0.970 |
| Pneumonia+TB                   | 0.32 (0.05–2.32) | 0.261 |
| Post-ICS TB                    | 2.52 (1.22–5.22) | 0.012 |
| Post-ICS pneumonia             | 1.28 (0.73–2.26) | 0.389 |
| Post-ICS pneumonia+TB          | 2.31 (0.84–6.38) | 0.105 |
| Comorbidities                  |              |
| COPD                           | 1.26 (1.05–1.53) | 0.015 |
| Smoking related cancers        | 1.61 (0.83–3.11) | 0.158 |
| Diabetes                       | 0.99 (0.80–1.22) | 0.912 |
| Hyperlipidemia                 | 0.82 (0.63–1.06) | 0.127 |
| Liver cirrhosis                | 0.86 (0.41–1.82) | 0.695 |
| Chronic renal disease          | 1.47 (0.99–2.18) | 0.052 |
| Autoimmune disease             | 0.87 (0.51–1.49) | 0.621 |
| Atopy dermatitis               | 0.60 (0.31–1.16) | 0.129 |
| Rhinosinusitis                 | 0.91 (0.76–1.09) | 0.293 |
| Medications                    |              |
| OCS                            | 0.83 (0.66–1.05) | 0.123 |
| LABA                           | 1.13 (0.90–1.42) | 0.300 |
| SABA                           | 1.14 (0.94–1.39) | 0.180 |
| LTRA                           | 0.99 (0.71–1.39) | 0.981 |
| Theophylline                   | 1.31 (1.04–1.66) | 0.023 |
| Statins                        | 1.19 (0.91–1.55) | 0.209 |
| Aspirin                        | 1.07 (0.90–1.27) | 0.451 |
| Sex (%)                        |              |
| Men                            | 2.15 (1.76–2.62) | <0.001 |
| Women                          | Reference     |
| Age group                      |              |
| 20–39                          | 0.11 (0.03–0.46) | 0.002 |
| 40–59                          | Reference     |
| 60–79                          | 3.84 (2.90–5.07) | <0.001 |
| ≥80                            | 6.12 (4.43–8.45) | <0.001 |
| No. of outpatient visits for lung disease 2 years after the index date* | | |
| ≤15                            | Reference     |
| >15                            | 1.28 (1.04–1.58) | 0.019 |
| No. of inpatient visits for lung disease 2 years after the index date* | | |
| 0                              | Reference     |
| >1                             | 0.95 (0.74–1.21) | 0.654 |
| Urbanization                   | | |
| High                           | Reference     |
| Mid                            | 1.10 (0.92–1.31) | 0.287 |

(Continued)
In this study, there was a close association between post-ICS TB and lung cancer in patients with asthma. Jian and colleagues reported a stronger association between coexisting asthma/TB and lung cancer in men and women [5]. Their HRs were 2.12 (95% CI, 1.59–2.83) and 2.21 (95% CI, 1.28–3.81), respectively. Biologically, the effects of post-ICS TB on lung cancer may be explained by asthma and TB-related chronic inflammatory processes of lung, corticosteroids-induced compromised immune clearance of Mycobacterium tuberculosis and malignant cells that predispose to lung cancer. However, this study found no statistically significant additive effect of post-ICS pneumonia and TB on lung cancer (HR, 2.31; 95% CI, 0.84–6.38; p = 0.105). The prevalence of pneumonia+TB in ICS and non-ICS users was 0.8 (88/10,904) and 0.5% (193/43,616), respectively. Lung cancer risk was found to be higher in patients with more than one of the lung diseases (TB, pneumonia, chronic bronchitis and asthma) [23]. This may have been due to the relatively small sample size. Nonetheless, such findings warrant further investigations.

In the US, the National Lung Screening Trial (NLST) included asymptomatic individuals aged 55 to 74 years who had a history of at least 30 pack-years of smoking and who were either current smokers or had been smokers within the previous 15 years [35]. Results showed a 20% relative reduction in lung cancer-specific mortality with the use of 3 screenings (at 1-year intervals) with low-dose computed tomography (CT) than with the use of chest radiography. Wu et al. retrospectively analyzed the medical records of 1,763 asymptomatic individuals who underwent self-paid low-dose CT in Taiwan [36]. Results showed that 8.4% (148/1,763) of study individuals were eligible for lung cancer screening based on the NLST criteria and only one participant was diagnosed with lung cancer. Twenty-four individuals (24/1615) who did not meet NLST eligible criteria were diagnosed with lung cancer. They also found that female and a family history of lung cancer were the 2 most important predictors of lung cancer. Chen et al. retrospectively reviewed the medical records of 3,339 asymptomatic individuals who received annual medical examinations and reported 34 cases of lung cancer [37]. The overall cancer detection rate was 1.02%. Individuals who were younger than 50 years with a positive family history of all types of cancers in first-degree relatives were at elevated risk of the disease (detection rate, 6.2%; 8/129). From above studies, a family history of cancer was the most important predictor of lung cancer in Taiwan.

Studies to investigate lung cancer incidence in Taiwanese smokers and non-smokers are scarce. The population in Taiwan is approximately 23 million and the smoking rate among adults in Taiwan has decreased from 23.0% (men, 39.2; women, 5.4%) in 2007 to 19.5% (33.6 and 4.6%) in 2011, respectively [38]. Smoking history has been officially included in the TCRD since 2011. Among patients diagnosed with lung cancer in 2011 and 2012 (n = 21,536), 42.4% were smokers [39]. The age-standardized incidence rate of lung cancer in Taiwan in 2011 was 34.0/100,000 (men, 45.0/100,000; women, 25.2/100,000) [40]. In this study, the 5-year cumulative incidence of lung cancer in patients with post-ICS TB was 6.4%. Post-ICS TB was an important predictor for lung cancer.

| Table 2. (Continued) | All patients with asthma |
|-----------------------|-------------------------|
|                       | HR (95% CI)             | P-value |
| Low                   | 1.06 (0.83–1.34)        | 0.658    |

CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; ICS, inhaled corticosteroid; LABA, long-acting inhaled beta-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting beta-agonist; TB, pulmonary tuberculosis.

*Index date was defined as the date of initiation of ICS.

doi:10.1371/journal.pone.0159683.t002
Established risk factors for lung cancer include tobacco smoke, genetic factor, alcohol, and occupation exposure. Smoking is the major risk factor for lung cancer. However, most of the female lung cancer patients in Taiwan were non-smokers [41]. Evidence shows that lung cancer tends to aggregate in families [42, 43]. A positive association has been reported between all cancer history of first-degree relatives and the risk of lung cancer among lifetime nonsmokers in Hong Kong (OR, 2.14; 95%CI, 1.30–3.54) [23]. A family history of lung cancer has been reported as a significant predictor of lung cancer for non-smoking females in Taiwan (OR, 5.7; 95% CI, 1.9–16.9) [44]. This shows that genetic susceptibility might influence the risk of lung cancer. Alcohol consumption has been associated with a modest increase in lung cancer risk (i.e., for ≥7 drinks/day, the HR = 1.11; 95% CI, 1.00–1.24) compared with nondrinking [45]. Among the possible causes of lung cancer, occupational risk factors are potentially preventable. Lung cancer risks were higher in workers who were employed in asbestos-processing industries, metal foundries and petrochemical industries [2, 46].

The strengths of this study were numerous. First, our study was a retrospective cohort study which included large sample size and long follow-up duration. In addition, the temporal relationship between post-ICS pulmonary infections and lung cancer is difficult to evaluate in case–control studies. Second, there was the completeness of cancer case ascertainment, hence allowing the little possibility for recall and selection bias. Nevertheless, this study had some limitations. First, detection bias might have been possible because of the frequent hospital visits which might have led to a higher detection rate of TB and early-stage lung cancer. Second, pulmonary comorbidities may significantly mask symptoms and delay the diagnosis of lung cancer or may even prevent a full diagnostic evaluation with the proper staging of the disease. We excluded patients who were diagnosed with TB or pneumonia before or within 3 months after the index date. Third, the national databases do not contain detailed information regarding smoking, alcohol, radon exposure, occupational exposures, diet preference, and family history, all of which may be risk factors for lung cancer.

Conclusions
We found that post-ICS TB conferred a higher risk of lung cancer than exposure to pulmonary diseases among non-users of ICS. Because of the high mortality associated with lung cancer, screening programs should include post-ICS TB.

Acknowledgments
The authors acknowledge the Department of Statistics, Ministry of Health and Welfare of Taiwan for providing the NHIRD, TCRD and NDRD. The descriptions or conclusions herein do not represent the viewpoint of the Bureau.

Author Contributions
Conceived and designed the experiments: ZHJ JYH MFW YPL. Performed the experiments: JYH CCL CCH. Analyzed the data: ZHJ FCFL KMJ MCW. Contributed reagents/materials/analysis tools: WYK HHP. Wrote the paper: ZHJ ONN HHP.

References
1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310:591–608. doi:10.1001/jama.2013.13805 PMID: 23842577
2. Le CH, Ko YC, Cheng LS, Lin YC, Lin HJ, Huang MS, et al. The heterogeneity in risk factors of lung cancer and the difference of histologic distribution between genders in Taiwan. Cancer Causes Control. 2001; 12:289–300. PMID: 11456224
3. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003; 5:46–62. PMID: 14596704

4. Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014; 816:1–23. doi: 10.1007/978-3-0348-0837-8_1 PMID: 24818717

5. Jian ZH, Lung CC, Huang JY, Ko PC, Jan SR, Ndi Nfor O, et al. The coexistence of common pulmonary diseases on the histologic type of lung cancer in both genders in Taiwan: a STROBE-compliant article. Medicine. 2014; 93:e127. doi: 10.1097/MD.0000000000000127 PMID: 25501048

6. Huang JY, Jian ZH, Nfor ON, Ku WY, Ko PC, Lung CC, et al. The effects of pulmonary diseases on histologic types of lung cancer in both sexes: a population-based study in Taiwan. BMC cancer. 2015; 15:834. doi: 10.1186/s12885-015-1847-z PMID: 26526071

7. Lin TY, Huang WY, Lin JC, Lin CL, Sung FC, Kao CH, et al. Increased lung cancer risk among patients with pneumococcal pneumonia: a nationwide population-based cohort study. Lung. 2014; 192:159–65. doi: 10.1007/s00408-013-9523-z PMID: 24150601

8. Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, et al. Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007. Acta Derm Venereol. 2010; 90:589–94. doi: 10.2340/00015555-0963 PMID: 21057741

9. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996; 153:551–556. PMID: 8564096

10. Ahmadiafshar A, Ahmadiafshar S. Efficacy and safety of inhaled and intranasal corticosteroids. Antiinflamm Antiallergy Agents Med Chem. 2014; 13:83–87. PMID: 25175908

11. Williams SG, Schmidt DK, Redd SC, Storms W. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep. 2003; 52:1–8.

12. Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respir Med. 2013; 107:1222–1233. doi: 10.1016/j.rmed.2012.12.002 PMID: 23768737

13. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:712–719. PMID: 17185647

14. Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009; 103:85–90. doi: 10.1016/j.rmed.2008.07.024 PMID: 18793832

15. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013; 68:1105–13. doi: 10.1136/thoraxjnl-2012-203175 PMID: 23749841

16. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med. 2010; 104:246–252. doi: 10.1016/j.rmed.2009.10.002 PMID: 19879745

17. Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer. 2011; 117:618–24. doi: 10.1002/cncr.25616 PMID: 20886634

18. Huang JY, Jian ZH, Ndi Nfor O, Jhang KM, Ku WY, Ko PC, et al. The Impact of Coexisting Asthma, Chronic Obstructive Pulmonary Disease and Tuberculosis on Survival in Patients with Lung Squamous Cell Carcinoma. PloS one. 2015; 10:e0133367. doi: 10.1371/journal.pone.0133367 PMID: 26196516

19. Jian ZH, Huang JY, Ko PC, Jan SR, Ndi Nfor ON, Lung CC, et al. Impact of coexisting pulmonary diseases on survival of patients with lung adenocarcinoma: a STROBE-compliant article. Medicine. 2015; 94: e443. doi: 10.1097/MD.0000000000000443 PMID: 25634179

20. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006; 55:19–26. PMID: 16463407

21. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. 2009; 65:853–871. doi: 10.1007/s00228-009-0682-z PMID: 19557399

22. Wu AH, Fontham ET, Reynolds P, Greenberg RS, Buffer P, Liff J, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol. 1995; 141:1023–1032. PMID: 7771438

23. Wang XR, Yu IT, Chiu YL, Qiu H, Fu Z, Goggin W, et al. Previous pulmonary disease and family cancer history increase the risk of lung cancer among Hong Kong women. Cancer Causes Control. 2009; 20:757–763. doi: 10.1007/s10552-008-9289-4 PMID: 19169896
24. Boffetta P, Ye W, Boman G, Nyren. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur Respir J. 2002; 19:127–133. PMID: 11843311

25. Rosenberger A, Bickeboller H, McCormack V, Brenner DR, Duell EJ, Tjonneland A, et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis. 2012; 33:587–597. doi: 10.1093/carcin/bgr307 PMID: 22198214

26. Kok VC, Hong JT, Huang HK, Chao TM, Hong YF. Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis. Ther Clin Risk Manag. 2015; 11:489–499. doi: 10.2147/TCRM.S80793 PMID: 25848295

27. Boumpas DT, Chroulos GS, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119:1198–1208. PMID: 8239251

28. The American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000; 161:S221–247. PMID: 10764341

29. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis. Ther Clin Risk Manag. 2015; 11:489–499. doi: 10.2147/TCRM.S80793 PMID: 25848295

30. Chung WS, Chen YF, Hsu JC, Yang WT, Chen SC, Chiang JY. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study. Int J Clin Pract. 2014; 68:1193–1199. doi: 10.1111/ijcp.12459 PMID: 25848295

31. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One. 2011; 6:e17479. doi:10.1371/journal.pone.0017479 PMID: 21483846

32. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395–409. doi: 10.1056/NEJMoa1102873 PMID: 21714641

33. Health Promotion Administration. Report from Adult Smoking Behavior Surveillance System. Health Promotion Administration, Ministry of Health and Welfare, Taiwan. 2016. Available:https://olap.hpa.gov.tw/en_US/Search/ListHealth1.aspx?menu=1&vid=1&mode=12&year=96

34. Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, et al. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget. 2016. Epub 2016/05/19. doi:10.18632/oncotarget.9338 PMID: 27191886. [Epub ahead of print]

35. Taiwan Cancer Registry. Cancer incidence and mortality rates in Taiwan. Taiwan Cancer Registry. 2016. Available: http://tcr.cph.ntu.edu.tw/main.php?Page=N2

36. Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Perng RP, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer. 2007; 110:1768–1775. PMID: 17879370

37. Brownson RC, Alavanja MC, Caporaso N, Berger E, Chang JC. Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers. Int J Epidemiol. 1997; 26:256–263. PMID: 9169159

38. Bremen K, Pohlabn H, Jahn I, Ahrens W, Jockel KH. Aggregation of lung cancer in families: results from a population-based case-control study in Germany. Am J Epidemiol. 2000; 152:497–505. PMID: 10997539
44. Wu PF, Lee CH, Wang MJ, Goggins WB, Chiang TA, Huang MS, et al. Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan. Eur J Cancer. 2004; 40:260–266. PMID: 14728941

45. Troche JR, Mayne ST, Freedman ND, Shebl FM, Abnet CC. The Association Between Alcohol Consumption and Lung Carcinoma by Histological Subtype. Am J Epidemiol. 2016; 183:110–121. doi: 10.1093/aje/kwv170 PMID: 26672017

46. Jockel KH, Ahrens W, Jahn I, Pohlabeln H, Bolm-Audorff U. Occupational risk factors for lung cancer: a case-control study in West Germany. Int J Epidemiol. 1998; 27:549–560. PMID: 9758106